Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
CAR-T cell
T cell
iPSC
iPSC-derived T cell
off-the-shelf, stem cells
tumor cell
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
30
04
2021
accepted:
24
05
2021
pubmed:
12
6
2021
medline:
15
12
2021
entrez:
11
6
2021
Statut:
ppublish
Résumé
Chimeric antigen receptor T (CAR-T) cell therapy has been increasingly conducted for cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the lack of a solid manufacturing process, T lymphocytes, and tumor-specific antigens. T cell source used in CAR-T cell therapy is derived predominantly from the patient's own T lymphocytes, which makes this approach impracticable to patients with progressive diseases and T leukemia. The generation of autologous CAR-T cells is time-consuming due to the lack of readily available T lymphocytes and is not applicable for third-party patients. Pluripotent stem cells, such as human induced pluripotent stem cells (hiPSCs), can provide an unlimited T cell source for CAR-T cell development with the potential of generating off-the-shelf T cell products. T-iPSCs (iPSC-derived T cells) are phenotypically defined, expandable, and as functional as physiological T cells. The combination of iPSC and CAR technologies provides an exciting opportunity to oncology and greatly facilitates cell-based therapy for cancer patients. However, T-iPSCs, in combination with CARs, are at the early stage of development and need further pre-clinical and clinical studies. This review will critically discuss the progress made in iPSC-derived T cells and provides a roadmap for the development of CAR iPSC-derived T cells and off-the-shelf T-iPSCs.
Identifiants
pubmed: 34114161
doi: 10.1007/s11095-021-03067-z
pii: 10.1007/s11095-021-03067-z
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
931-945Références
Wang Z, Cao YJ. Adoptive cell therapy targeting neoantigens: a frontier for cancer research. Front Immunol. 2020;11(176).
Rohaan MW, Wilgenhof S, Haanen J. Adoptive cellular therapies: the current landscape. Virchows Arch. 2019;474(4):449–61.
pubmed: 30470934
Milone MC, Bhoj VG. The pharmacology of T cell therapies. Molecular Therapy-Methods & Clinical Development. 2018;8:210–21.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.
pubmed: 29385370
pmcid: 29385370
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.
pubmed: 5882485
pmcid: 5882485
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42.
pubmed: 32242358
pmcid: 32242358
Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.
Srivastava S, Riddell SR. Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J Immunol. 2018;200(2):459–68.
pubmed: 29311388
Yang Y, Jacoby E, Fry TJ. Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol. 2015;22(6):509–15.
pubmed: 26390167
pmcid: 4636084
Sadeqi Nezhad M, Seifalian A, Bagheri N, Yaghoubi S, Karimi MH, Adbollahpour-Alitappeh M. Chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: how close are we to the treatment? Front Immunol. 2020;11(3062).
Abreu TR, Fonseca NA, Gonçalves N, Moreira JN. Current challenges and emerging opportunities of CAR-T cell therapies. J Control Release. 2020;319:246–61.
pubmed: 31899268
Birnbaum ME, Berry R, Hsiao Y-S, Chen Z, Shingu-Vazquez MA, Yu X, et al. Molecular architecture of the αβ T cell receptor–CD3 complex. Proc Natl Acad Sci. 2014;111(49):17576–81.
pubmed: 25422432
pmcid: 4267357
Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol. 2006;24:419–66.
pubmed: 16551255
Wang X, Rivière I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015.
pubmed: 27347557
pmcid: 4909095
Townsend MH, Bennion K, Robison RA, O’Neill KL. Paving the way towards universal treatment with allogenic T cells. Immunol Res. 2020:1–8.
Li C, Mei H, Hu Y. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. Briefings in functional genomics. 2020;19(3):175–82.
pubmed: 31950135
pmcid: 7239310
Liu J, Zhou G, Zhang L, Zhao Q. Building potent chimeric antigen receptor T cells with CRISPR genome editing. Front Immunol. 2019;10:456.
pubmed: 30941126
pmcid: 6433930
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.
pubmed: 18035408
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–20.
pubmed: 18029452
Kim K, Zhao R, Doi A, Ng K, Unternaehrer J, Cahan P, et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol. 2011;29(12):1117–9.
pubmed: 22119740
pmcid: 3357310
Parrotta E, De Angelis MT, Scalise S, Candeloro P, Santamaria G, Paonessa M, et al. Two sides of the same coin? Unraveling subtle differences between human embryonic and induced pluripotent stem cells by Raman spectroscopy. Stem Cell Res Ther. 2017;8(1):271.
pubmed: 29183402
pmcid: 5706396
Wattanapanitch M. Recent updates on induced pluripotent stem cells in hematological disorders. Stem Cells Int. 2019;2019:5171032.
pubmed: 31191673
pmcid: 6525795
Liu G, David BT, Trawczynski M, Fessler RG. Advances in pluripotent stem cells: history, mechanisms, technologies, and applications. Stem Cell Rev Rep. 2020;16(1):3–32.
pubmed: 31760627
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.
pubmed: 16904174
Shi G, Jin Y. Role of Oct4 in maintaining and regaining stem cell pluripotency. Stem Cell Res Ther. 2010;1(5):39.
pubmed: 21156086
pmcid: 3025441
Kim D, Kim C-H, Moon J-I, Chung Y-G, Chang M-Y, Han B-S, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4(6):472–6.
pubmed: 19481515
pmcid: 2705327
Scheper W, Copray S. The molecular mechanism of induced pluripotency: a two-stage switch. Stem Cell Rev Rep. 2009;5(3):204–23.
pubmed: 19551525
Nandan MO, Yang VW. The role of Krüppel-like factors in the reprogramming of somatic cells to induced pluripotent stem cells. Histol Histopathol. 2009;24(10):1343–55.
pubmed: 19688699
pmcid: 2753264
Niwa H, Ogawa K, Shimosato D, Adachi K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature. 2009;460(7251):118–22.
pubmed: 19571885
Shyh-Chang N, Daley GQ. Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell. 2013;12(4):395–406.
pubmed: 23561442
pmcid: 3652335
Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, et al. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem. 2005;280(26):24731–7.
pubmed: 15860457
Wu Y, Zhang Y, Mishra A, Tardif SD, Hornsby PJ. Generation of induced pluripotent stem cells from newborn marmoset skin fibroblasts. Stem Cell Res. 2010;4(3):180–8.
pubmed: 20363201
pmcid: 2875323
Liu X, Li W, Fu X, Xu Y. The immunogenicity and immune tolerance of pluripotent stem cell derivatives. Front Immunol. 2017;8:645.
pubmed: 28626459
pmcid: 5454078
Yamanaka S. Pluripotent stem cell-based cell therapy-promise and challenges. Cell Stem Cell. 2020;27(4):523–31.
pubmed: 33007237
Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181–92.e5.
pubmed: 30082067
pmcid: 6084450
Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31(10):928–33.
pubmed: 23934177
pmcid: 5722218
Fernandez TS, de Souza Fernandez C, Mencalha AL. Human induced pluripotent stem cells from basic research to potential clinical applications in cancer. Biomed Res Int. 2013;2013:430290.
pmcid: 3830845
Crook JM, Hei D, Stacey G. The international stem cell banking initiative (ISCBI): raising standards to bank on. In Vitro Cell Dev Biol Anim. 2010;46(3–4):169–72.
pubmed: 20195786
Huang C-Y, Liu C-L, Ting C-Y, Chiu Y-T, Cheng Y-C, Nicholson MW, et al. Human iPSC banking: barriers and opportunities. J Biomed Sci. 2019;26(1):87-.
Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, Fujii S, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell. 2013;12(1):31–6.
pubmed: 23290135
Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, Mackall C, et al. Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy. 2013;15(11):1406–15.
pubmed: 23992830
pmcid: 4141724
Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013;12(1):114–26.
pubmed: 23290140
Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011;11(4):268–77.
pubmed: 21390058
Blelloch R, Venere M, Yen J, Ramalho-Santos M. Generation of induced pluripotent stem cells in the absence of drug selection. Cell Stem Cell. 2007;1(3):245–7.
pubmed: 18371358
pmcid: 2894698
Ban H, Nishishita N, Fusaki N, Tabata T, Saeki K, Shikamura M, et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A. 2011;108(34):14234–9.
pubmed: 21821793
pmcid: 3161531
Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell. 2011;8(6):633–8.
pubmed: 21620789
Narsinh KH, Jia F, Robbins RC, Kay MA, Longaker MT, Wu JC. Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat Protoc. 2011;6(1):78–88.
pubmed: 21212777
Sohn YD, Somasuntharam I, Che PL, Jayswal R, Murthy N, Davis ME, et al. Induction of pluripotency in bone marrow mononuclear cells via polyketal nanoparticle-mediated delivery of mature microRNAs. Biomaterials. 2013;34(17):4235–41.
pubmed: 23489923
pmcid: 3740735
Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science. 2008;322(5903):945–9.
pubmed: 18818365
pmcid: 3987909
Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010;7(5):618–30.
pubmed: 20888316
pmcid: 3656821
Yusa K, Rad R, Takeda J, Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods. 2009;6(5):363–9.
pubmed: 19337237
pmcid: 2677165
Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009;4(5):381–4.
pubmed: 19398399
Zhou W, Freed CR. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells. 2009;27(11):2667–74.
pubmed: 19697349
Haridhasapavalan KK, Borgohain MP, Dey C, Saha B, Narayan G, Kumar S, et al. An insight into non-integrative gene delivery approaches to generate transgene-free induced pluripotent stem cells. Gene. 2019;686:146–59.
pubmed: 30472380
Abujarour R, Valamehr B, Robinson M, Rezner B, Vranceanu F, Flynn P. Optimized surface markers for the prospective isolation of high-quality hiPSCs using flow cytometry selection. Sci Rep. 2013;3:1179-.
Bharathan SP, Manian KV, Aalam SMM, Palani D, Deshpande PA, Pratheesh MD, et al. Systematic evaluation of markers used for the identification of human induced pluripotent stem cells. Biol Open. 2017;6(1):100–8.
pubmed: 28089995
pmcid: 5278432
Paik EJ, O’Neil AL, Ng S-Y, Sun C, Rubin LL. Using intracellular markers to identify a novel set of surface markers for live cell purification from a heterogeneous hIPSC culture. Sci Rep. 2018;8(1):804.
pubmed: 29339826
pmcid: 5770419
Singh U, Quintanilla RH, Grecian S, Gee KR, Rao MS, Lakshmipathy U. Novel live alkaline phosphatase substrate for identification of pluripotent stem cells. Stem Cell Rev Rep. 2012;8(3):1021–9.
pubmed: 22426885
Kumazaki T, Kurata S, Matsuo T, Mitsui Y, Takahashi T. Establishment of human induced pluripotent stem cell lines from normal fibroblast TIG-1. Hum Cell. 2011;24(2):96–103.
pubmed: 21562774
Secher JO, Ceylan A, Mazzoni G, Mashayekhi K, Li T, Muenthaisong S, et al. Systematic in vitro and in vivo characterization of leukemia-inhibiting factor- and fibroblast growth factor-derived porcine induced pluripotent stem cells. Mol Reprod Dev. 2017;84(3):229–45.
pubmed: 28044390
pmcid: 6221014
Ito E, Miyagawa S, Takeda M, Kawamura A, Harada A, Iseoka H, et al. Tumorigenicity assay essential for facilitating safety studies of hiPSC-derived cardiomyocytes for clinical application. Sci Rep. 2019;9(1):1881.
pubmed: 30760836
pmcid: 6374479
Xiang M, Lu M, Quan J, Xu M, Meng D, Cui A, et al. Direct in vivo application of induced pluripotent stem cells is feasible and can be safe. Theranostics. 2019;9(1):290–310.
pubmed: 30662568
pmcid: 6332789
Elliott AM, Elliott KA, Kammesheidt A. High resolution array-CGH characterization of human stem cells using a stem cell focused microarray. Mol Biotechnol. 2010;46(3):234–42.
pubmed: 20524159
Jang Y, Choi J, Park N, Kang J, Kim M, Kim Y, et al. Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering. Exp Mol Med. 2019;51(1):1–11.
pubmed: 31819031
Nazareth EJP, Ostblom JEE, Lücker PB, Shukla S, Alvarez MM, Oh SKW, et al. High-throughput fingerprinting of human pluripotent stem cell fate responses and lineage bias. Nat Methods. 2013;10(12):1225–31.
pubmed: 24141495
pmcid: 5061564
Popp B, Krumbiegel M, Grosch J, Sommer A, Uebe S, Kohl Z, et al. Need for high-resolution genetic analysis in iPSC: results and lessons from the ForIPS consortium. Sci Rep. 2018;8(1):17201.
pubmed: 30464253
pmcid: 6249203
Quinlan AR, Boland MJ, Leibowitz ML, Shumilina S, Pehrson SM, Baldwin KK, et al. Genome sequencing of mouse induced pluripotent stem cells reveals retroelement stability and infrequent DNA rearrangement during reprogramming. Cell Stem Cell. 2011;9(4):366–73.
pubmed: 21982236
pmcid: 3975295
Ramos-Mejía V, Montes R, Bueno C, Ayllón V, Real PJ, Rodríguez R, et al. Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD34+ progenitors. PLoS One. 2012;7(4):e35824.
pubmed: 22545141
pmcid: 3335819
Taapken SM, Nisler BS, Newton MA, Sampsell-Barron TL, Leonhard KA, McIntire EM, et al. Karyotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells. Nat Biotechnol. 2011;29(4):313–4.
pubmed: 21478842
Dekel-Naftali M, Aviram-Goldring A, Litmanovitch T, Shamash J, Reznik-Wolf H, Laevsky I, et al. Screening of human pluripotent stem cells using CGH and FISH reveals low-grade mosaic aneuploidy and a recurrent amplification of chromosome 1q. Eur J Hum Genet. 2012;20(12):1248–55.
pubmed: 22713809
pmcid: 3499752
Sarafian R, Morato-Marques M, Borsoi J, Pereira LV. Monitoring cell line identity in collections of human induced pluripotent stem cells. Stem Cell Res. 2018;28:66–70.
pubmed: 29433076
Sullivan S, Stacey GN, Akazawa C, Aoyama N, Baptista R, Bedford P, et al. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med. 2018;13(7):859–66.
pubmed: 30205750
La Motte-Mohs RN, Herer E, Zúñiga-Pflücker JC. Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood. 2005;105(4):1431–9.
pubmed: 15494433
Maeda T, Nagano S, Ichise H, Kataoka K, Yamada D, Ogawa S, et al. Regeneration of CD8αβ T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity. Cancer Res. 2016;76(23):6839–50.
pubmed: 27872100
Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, et al. Enhancing t cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell. 2018;23(6):850–8.e4.
Kim SJ, Kim BS, Ryu SW, Yoo JH, Oh JH, Song CH, et al. Hematopoietic differentiation of embryoid bodies derived from the human embryonic stem cell line SNUhES3 in co-culture with human bone marrow stromal cells. Yonsei Med J. 2005;46(5):693–9.
pubmed: 16259069
pmcid: 2810577
Chen X, Lei F, Wang L, Xiong X, Song J. Generation of tumor antigen-specific cytotoxic T lymphocytes from pluripotent stem cells. Methods Mol Biol. 1884;2019:43–55.
Weisel KC, Gao Y, Shieh J-H, Moore MAS. Stromal cell lines from the aorta-gonado-mesonephros region are potent supporters of murine and human hematopoiesis. Exp Hematol. 2006;34(11):1505–16.
pubmed: 17046570
Campbell A, Wicha MS, Long M. Extracellular matrix promotes the growth and differentiation of murine hematopoietic cells in vitro. J Clin Invest. 1985;75(6):2085–90.
pubmed: 4008654
pmcid: 425570
Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science. 1994;265(5175):1098–101.
pubmed: 8066449
Iriguchi S, Yasui Y, Kawai Y, Arima S, Kunitomo M, Sato T, et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat Commun. 2021;12(1):430.
pubmed: 33462228
pmcid: 7814014
Cheadle E, Rothwell D, Bridgeman J, Sheard V, Hawkins R, Gilham D. Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells. Gene Ther. 2012;19(11):1114–20.
pubmed: 22130449
Luther DC, Lee YW, Nagaraj H, Scaletti F, Rotello VM. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. Expert Opin Drug Deliv. 2018;15(9):905–13.
pubmed: 30169977
pmcid: 6295289
Ou J, Si Y, Tang Y, Salzer GE, Lu Y, Kim S, et al. Novel biomanufacturing platform for large-scale and high-quality human T cells production. J Biol Eng. 2019;13(1):34.
pubmed: 31044002
pmcid: 6480708
Palomero T, Ferrando A. Targeted cellular immunotherapy for T cell malignancies. Nat Med. 2017;23(12):1402–3.
pubmed: 29216040
pmcid: 5848213
Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):580–8.
pubmed: 27913532
pmcid: 6142501
Iyer RK, Bowles PA, Kim H, Dulgar-Tulloch A. Industrializing autologous adoptive immunotherapies: manufacturing advances and challenges. Frontiers in Medicine. 2018;5(150).
Papathanasiou MM, Stamatis C, Lakelin M, Farid S, Titchener-Hooker N, Shah N. Autologous CAR T-cell therapies supply chain: challenges and opportunities? Cancer Gene Ther. 2020;27(10):799–809.
pubmed: 31932694
Nagano S, Maeda T, Ichise H, Kashima S, Ohtaka M, Nakanishi M, et al. High frequency production of T cell-derived iPSC clones capable of generating potent cytotoxic T cells. Mol Ther Methods Clin Dev. 2020;16:126–35.
pubmed: 31970197
Loh YH, Hartung O, Li H, Guo C, Sahalie JM, Manos PD, et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell. 2010;7(1):15–9.
pubmed: 20621044
pmcid: 2913590
Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 2010;7(1):11–4.
pubmed: 20621043
Staerk J, Dawlaty MM, Gao Q, Maetzel D, Hanna J, Sommer CA, et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010;7(1):20–4.
pubmed: 20621045
pmcid: 2917234
Netsrithong R, Promnakhon N, Boonkaew B, Vatanashevanopakorn C, Pattanapanyasat K, Wattanapanitch M. Generation of two induced pluripotent stem cell lines (MUSIi011-a and MUSIi011-B) from peripheral blood T lymphocytes of a healthy individual. Stem Cell Res. 2019;39:101487.
pubmed: 31229899
Saito H, Okita K, Fusaki N, Sabel MS, Chang AE, Ito F. Reprogramming of melanoma tumor-infiltrating lymphocytes to induced pluripotent stem cells. Stem Cells Int. 2016;2016:8394960.
pubmed: 27057178
Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol. 2002;3(1):83–90.
pubmed: 11743585
Liem NT, Van Phong N, Kien NT, Anh BV, Huyen TL, Thao CT, et al. Phase I clinical trial using autologous ex vivo expanded nk cells and cytotoxic t lymphocytes for cancer treatment in vietnam. Int J Mol Sci. 2019;20(13).
Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535–46.
pubmed: 19451549
pmcid: 2929689
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126–9.
pubmed: 16946036
pmcid: 2267026
Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med. 2013;5(174):174ra27.
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–7.
pubmed: 21498393
pmcid: 3131487
Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–99.
pubmed: 31900462
Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev. 2010;36(7):528–38.
pubmed: 20381970
pmcid: 2921454
Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol. 2007;60(12):1373–7.
pubmed: 18042693
pmcid: 2095573
Perdomo-Celis F, Taborda NA, Rugeles MT. CD8+ T-Cell Response to HIV Infection in the Era of Antiretroviral Therapy. Front Immunol. 2019;10(1896).
Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda T, Shingai N, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant. 2020;26:307–15.
Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817–28.
pubmed: 21849486
pmcid: 3208293
Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21(11):2122–9.
pubmed: 23831595
pmcid: 3831035
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–54.
pubmed: 29226764
pmcid: 5788566
Rouce RH, Fousek K, Ahmed N, Gottschalk S, Savoldo B, Dotti G, et al. Safety of multiple doses of CAR T cells. American Society of Hematology Washington, DC; 2015.
Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, Le Priol J, et al. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood. 2016;128(8):1081–92.
pubmed: 27338100
Das RK, Vernau L, Grupp SA, Barrett DM. Naïve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 2019;9(4):492–9.
pubmed: 30630850
pmcid: 6676489
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499–503.
pubmed: 30275568
pmcid: 6511988
Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812–5.
pubmed: 31575532
pmcid: 6784521
Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290–7.
pubmed: 21926977
pmcid: 3192229
Hu Y, Wang J, Wei G, Yu J, Luo Y, Shi J, et al. A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia. Bone Marrow Transplant. 2019;54(8):1208–17.
pubmed: 30518980
Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(25):4129–39.
pubmed: 24055823
pmcid: 3862276
Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell. 2012;11(2):147–52.
pubmed: 22862941
pmcid: 22862941
Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, et al. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol. 2017;8:292.
pubmed: 28367149
pmcid: 5355494
Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell. 2019;24(4):566–78.e7.
Cunningham JJ, Ulbright TM, Pera MF, Looijenga LH. Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol. 2012;30(9):849–57.
pubmed: 22965062
Nianias A, Themeli M. Induced pluripotent stem cell (iPSC)-derived lymphocytes for adoptive cell immunotherapy: recent advances and challenges. Curr Hematol Malig Rep. 2019;14(4):261–8.
pubmed: 31243643
pmcid: 6647376
Duncan EJ, Gluckman PD, Dearden PK. Epigenetics, plasticity, and evolution: how do we link epigenetic change to phenotype? J Exp Zool B Mol Dev Evol. 2014;322(4):208–20.
pubmed: 24719220
Keller A, Dziedzicka D, Zambelli F, Markouli C, Sermon K, Spits C, et al. Genetic and epigenetic factors which modulate differentiation propensity in human pluripotent stem cells. Hum Reprod Update. 2018;24(2):162–75.
pubmed: 29377992
Yadav RK, Ali A, Kumar S, Sharma A, Baghchi B, Singh P, et al. CAR T cell therapy: newer approaches to counter resistance and cost. Heliyon. 2020;6(4):e03779.
pubmed: 32322738
pmcid: 7171532